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Abstract 16 
Since drug based inhibition of dipeptidyl peptidase IV (DPP-IV) is employed in type 2 (T2D) 17 
diabetes therapy, food protein hydrolysates which inhibit DPP-IV may also have potential in the 18 
management of T2D. Specific peptide motifs, consisting of an N-terminal Trp and/or a Pro at 19 
position 2, have been associated with relatively potent inhibition of DPP-IV. Different modes of 20 
inhibition which may, or may not, involve the active site of DPP-IV have been identified. Animal 21 
studies have shown that food protein hydrolysates having in vitro DPP-IV inhibitory activity 22 
generally yield antidiabetic effects in vivo. However, clear evidence of such effects in humans is 23 
still required in order to establish the potential role of food protein hydrolysates in the 24 
management of T2D. 25 
 26 
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Introduction 28 
Type 2 diabetes (T2D) is a major component of the metabolic syndrome. It has been shown to 29 
affect a growing number of people worldwide. While the etiology of T2D is not fully understood 30 
a link with obesity or high abdominal body fat content has been proposed. The role of food 31 
proteins in the regulation of serum glucose in humans has been demonstrated in several human 32 
intervention studies [for reviews, see: 1, 2, 3]. Human intervention studies with food proteins and 33 
food protein hydrolysates have involved a wide range of dietary proteins originating from animal 34 
and marine as well as plant sources [4-6]. However, the mechanism(s) of action explaining the 35 
antidiabetic effects observed are currently not fully understood. It is thought that dietary amino 36 
acids and short peptides may impact in a number of ways including: (a) the direct stimulation of 37 
pancreatic cells leading to increased insulin secretion, (b) inhibition of metabolic enzymes 38 
involved in the regulation of serum glucose, such as dipeptidyl peptidase IV (DPP-IV) and -39 
glucosidase, and (c) secretion of incretins (i.e., glucose dependent insulinotropic polypeptide 40 
(GIP) and glucagon-like peptide-1 (GLP-1)). 41 
DPP-IV is an ubiquitous enzyme which has been shown to cleave and inactivate GLP-1 and GIP 42 
in the post-prandial phase, leading to a loss in their insulinotropic activity [7]. DPP-IV inhibition 43 
is currently a key target in the treatment of T2D. In this context, different DPP-IV inhibitory 44 
drugs, belonging to a class known as gliptins, have been developed and marketed [8]. Gliptins 45 
generally have a high potency, with a half maximal inhibitory concentration (IC50) in the nM 46 
range. Interestingly, over the past 30 years, different naturally-derived peptides have been shown 47 
to inhibit DPP-IV. DPP-IV inhibitory peptide sequences have notably been identified within food 48 
proteins. The DPP-IV inhibitory properties of food protein hydrolysates and associated peptides 49 
have recently been reviewed [1, 3, 9, 10]. To date, the most potent DPP-IV inhibitory peptide is 50 
Ile-Pro-Ile (diprotin A), which was originally identified in Bacillus cereus culture filtrates [11]. 51 
Ile-Pro-Ile is also present in several dietary proteins such as bovine -casein, chicken egg 52 
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ovotransferrin and the phycoerythrin β subunit from the macroalga Palmaria palmata [12]. 53 
The aim of this review was to assess the current literature in respect to food protein 54 
hydrolysates/peptides and their DPP-IV inhibitory properties. The link between DPP-IV 55 
inhibition and antidiabetic effects was also assessed with the view of determining the potential of 56 
food protein hydrolysates for the management of T2D. 57 
Potential food protein sources of DPP-IV inhibitory peptides 58 
Different dietary proteins have been identified as a source of DPP-IV inhibitory peptides using in 59 
silico approaches. In silico approaches have focused on researching previously identified DPP-IV 60 
inhibitory peptide sequences within various food proteins. The outcomes of these studies indicate 61 
that milk proteins are particularly rich in DPP-IV inhibitory peptide motifs [12, 13]. The 62 
limitations of in silico approaches reside in the necessity to subsequently develop a strategy (i.e., 63 
enzymatic hydrolysis or fermentation) to release the target peptides from the protein. 64 
To date, most of the in vitro studies appear to have used enzymatic hydrolysis of food proteins to 65 
release DPP-IV inhibitory peptides [14-18]. There are a limited number of studies which 66 
demonstrate that microbial fermentation could also be utilized for the generation of DPP-IV 67 
inhibitory peptides. Water soluble extracts from cheese, for example, have been identified for 68 
their DPP-IV inhibitory properties [19]. Food protein hydrolysis is typically conducted in 69 
aqueous media using commercially available food-grade enzyme preparations which are added at 70 
a known enzyme to substrate ratio. Several studies have described the utilization of 71 
gastrointestinal (e.g., pepsin, trypsin, Pancreatin, Corolase PP), plant (e.g., bromelain and papain) 72 
or microbial (e.g., Alcalase, Flavourzyme and Protamex) [14, 15, 18, 20-24] enzyme preparations 73 
to generate food protein hydrolysates with DPP-IV inhibitory properties. The hydrolysis 74 
conditions (i.e., pH and temperature) are generally chosen to correspond to the optimum 75 
conditions for the enzyme activity employed with hydrolysis durations of up to several hours to 76 
ensure the release of bioactive peptides. Further fractionation of food protein hydrolysates, using 77 
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techniques such as ultrafiltration, solid phase extraction and chromatographic (reverse-phase, 78 
cation-exchange, size-exclusion and thin layer) separations, have been used to obtain fractions 79 
enriched in more potent DPP-IV inhibitory peptides [16, 18, 25-29]. 80 
Generally, the percentage of DPP-IV inhibition is assessed following incubation of DPP-IV with 81 
the peptides/hydrolysates in the presence of a chromogenic substrate (e.g., Gly-Pro-p-nitroanilide 82 
(pNA), Gly-Pro-aminomethylcoumarin (AMC) or Gly-Pro-aminoluciferin). Various in vitro 83 
protocols, which may vary in terms of the origin of DPP-IV (human recombinant vs. animal 84 
extract), nature of the DPP-IV substrate, enzyme to substrate ratio, duration of incubation and pH, 85 
have been described in the scientific literature to assess the DPP-IV inhibitory potential of food 86 
protein-derived peptides [12]. These differences in experimental conditions may explain, in 87 
certain instances, the variations observed for the potency of selected peptide sequences [30]. 88 
While most of the in vitro evaluation of DPP-IV inhibitory properties of food protein 89 
hydrolysates has been conducted with milk proteins [14, 15, 19, 31-34], alternative protein 90 
substrates from meat/animal skin [35-38], marine [18, 24, 39-41] and plant [17, 20-23, 42-45] 91 
origin have also been described in the literature. To date, the most potent in vitro DPP-IV 92 
inhibitory food protein hydrolysates have been reported for a peptic digest of bovine -93 
lactalbumin with an IC50 of 0.036 mg mL
-1
 [31] and a simulated gastro-intestinal digest 94 
(pepsin/Pancreatin) of Navy beans having an IC50 of 0.093 mg mL
-1
 [43]. Differences in DPP-IV 95 
inhibition potency between food protein hydrolysates may generally be explained by their unique 96 
peptide composition but may also to some extent be dependent on the assay employed [46]. 97 
Structure-function of DPP-IV inhibitors 98 
Research on DPP-IV inhibitory peptides from food protein sources is relatively novel (< 10 99 
years). Therefore, the number of peptide sequences which have been identified to date is limited 100 
(< 100 peptide sequences) [12, 33]. 101 
Elucidation of the physicochemical characteristics of peptides which are linked to DPP-IV 102 
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inhibition has been attempted. To date, there does not seem to be a consensus for the 103 
physicochemical characteristics of peptides which display relatively potent DPP-IV inhibition 104 
[47]. However, using a peptide alignment strategy, it has been shown that peptides containing a 105 
Trp at the N-terminus and a Pro at position 2 were generally relatively potent DPP-IV inhibitors, 106 
having IC50 values < 200 µM [12]. 107 
Several novel peptide sequences have been identified within food protein hydrolysates using 108 
liquid chromatography mass-spectrometric (LC-MS) analyses generally coupled with bioactivity-109 
driven fractionation approaches [16, 17, 19, 25, 29, 48]. In silico approaches have also allowed 110 
the identification of numerous peptide sequences [14, 34, 49, 50]. In addition, systematic 111 
approaches based on peptide library [51-53] and peptide array [48] technologies have enhanced 112 
DPP-IV inhibitory peptide sequence discovery as they allow rapid screening of hundreds of 113 
peptides. 114 
Mode of action of dietary DPP-IV inhibitory peptides 115 
Different modes of action of DPP-IV inhibitory peptides have been reported. These include 116 
competitive, non-competitive, uncompetitive and mixed-type inhibition [14, 17, 27, 50]. 117 
Knowledge of the mode of action of DPP-IV inhibitory peptides is important in order to 118 
understand their site of interaction with DPP-IV. This information is relevant when studying the 119 
molecular docking of peptides to the active site of DPP-IV [47]. 120 
In addition to the different modes of inhibition, it has been shown that specific peptides could act 121 
as DPP-IV substrates. Well-known examples of substrate inhibitors of DPP-IV are Ile-Pro-Ile and 122 
Val-Pro-Ala [54]. Food protein-derived peptides which are susceptible to DPP-IV cleavage have 123 
been classified as substrate or prodrug type inhibitors. Both substrate and prodrug peptide 124 
inhibitors comprise the typical motifs of DPP-IV substrates, i.e., Xaa-Pro- or Xaa-Ala- (where 125 
Xaa is an amino acid), at their N terminus. The cleavage of substrate inhibitors generally induces 126 
a loss/reduction in their bioactive properties. In contrast, in the case of prodrug inhibitors, DPP-127 
  7 
IV releases a more potent peptide. Interestingly, DPP-IV substrates have been predicted in silico 128 
to be released by the action of gastrointestinal enzymes on milk proteins [55]. In particular, a 129 
prodrug inhibitor, Leu-Pro-Leu-Pro-Leu (-casein (f 135-139), IC50 = 325 µM), was shown to be 130 
cleaved by DPP-IV in vitro, releasing a more potent compound Leu-Pro-Leu (IC50 = 241 µM). 131 
Therefore, the susceptibility of selected peptides to DPP-IV cleavage may have consequences in 132 
vivo, resulting in either a loss or an increase in their bioactive properties. 133 
In vitro studies have evaluated the effect of combining the DPP-IV inhibitory drug Sitagliptin 134 
with DPP-IV inhibitory peptides and a whey protein hydrolysate [26]. Using binary mixtures of 135 
Sitagliptin and dipeptide, together with an isobole approach, an additive effect on DPP-IV 136 
inhibition was shown in most instances [56]. Furthermore, synergistic effects were observed with 137 
Ile-Pro-Ile-Gln-Tyr (-casein (f 26-30)). While these effects have been observed in vitro, they 138 
need to be evaluated in vivo in order to determine if it is possible to combine drugs and food 139 
protein hydrolysates to, for example, restrict the possible side-effects associated with antidiabetic 140 
medicines [for review, see: 1]. 141 
Evidence of antidiabetic effects of food-protein derived DPP-IV inhibitory 142 
peptides in vivo 143 
The in vivo studies reporting the antidiabetic effects of DPP-IV inhibitory food protein 144 
hydrolysates, conducted to date, have been carried out in small animals. To our knowledge, six 145 
animal studies have been carried out to date with zein and meat protein hydrolysates [44], milk 146 
protein-derived peptides and hydrolysates [19, 32] along with gelatin hydrolysates from Atlantic 147 
salmon [39] halibut and tilapia [57] as well as porcine skin [36]. The outcomes of these studies 148 
are summarized in Table 1. All studies demonstrated a reduction in glycaemia. This was linked, 149 
only in certain instances, to an increase in post-prandial insulin level following ingestion of the 150 
hydrolysates [36, 39, 44, 57]. In addition, four animal studies have also demonstrated a reduction 151 
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in plasma DPP-IV activity, which was associated with an increase in the plasma level of active 152 
and/or total GLP-1 [36, 39, 44, 57]. 153 
To date, the study of DPP-IV inhibition by dietary peptides in humans is in its infancy. A number 154 
of studies have analyzed serum DPP-IV activity following nutritional interventions. However, to 155 
our knowledge, none of these studies have demonstrated a reduction in DPP-IV activity as a 156 
consequence of food-protein or hydrolysate consumption [58]. Interestingly, several fragments 157 
from bovine -casein have been reported in the gastrointestinal tract of humans [59], some of 158 
which had previously been described for their in vitro DPP-IV inhibitory properties [60] (Table 159 
2). However, to date, clear evidence for the bioavailability of food protein-derived peptides is 160 
limited [2], making it challenging to study their effects on systemic targets. This reinforces the 161 
relevance of targeting DPP-IV inhibition directly in the gut as opposed to the serum or other 162 
organs. To our knowledge, no study to date has evaluated DPP-IV inhibition directly in the gut of 163 
animals or humans in the context of nutritional interventions. 164 
Conclusions and perspectives 165 
To date, dietary protein hydrolysates with DPP-IV inhibitory properties have mainly been studied 166 
in vitro. A limited number of studies have been performed in vivo, with the majority of the 167 
studies being conducted in small animals. The contribution of DPP-IV inhibition to serum 168 
glucose regulatory effects following dietary protein and hydrolysate ingestion by humans is still 169 
unknown. However, it is likely that DPP-IV inhibition may play a role in the antidiabetic effects 170 
of intact and hydrolysed food proteins in humans. 171 
Analysis of the current literature has allowed identification of several opportunities to further 172 
study the DPP-IV inhibitory potential of food protein hydrolysates. There is a requirement for 173 
human intervention studies to better understand the role of DPP-IV inhibitory peptides in serum 174 
glucose regulation. The interactive effects between food protein-derived peptides in vivo and 175 
antidiabetic drugs is also worthy for future studies. Additional studies on the interaction of 176 
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peptides with secondary binding sites of DPP-IV are warranted as numerous non-competitive 177 
peptide sequences have been found to be relatively potent inhibitors of DPP-IV. Finally, 178 
utilization of in silico approaches may help in the identification of novel food protein sources of 179 
DPP-IV inhibitory peptides. This may allow valorization of underutilized proteins as well as the 180 
development of strategies for the release of potent DPP-IV inhibitory peptides. 181 
182 
  10 
Acknowledgements 183 
The work described herein was partially supported by Enterprise Ireland under Grant Number 184 
TC2013-0001.185 
  11 
Conflicts of interests 186 
The authors declare that they have no conflict of interest. 187 
188 
  12 
References 189 
References 190 
Papers of particular interest, published within the period of review, have been highlighted as: 191 
*of special interest 192 
**of outstanding interest 193 
 194 
1. Lacroix IME, Li-Chan ECY: Overview of food products and dietary constituents with 195 
antidiabetic properties and their putative mechanisms of action: A natural approach to 196 
complement pharmacotherapy in the management of diabetes. Mol Nutr Food Res 197 
2014,58:61-78. 198 
*2. Nongonierma AB, FitzGerald RJ: The scientific evidence for the role of milk protein-199 
derived bioactive peptides in humans: A Review. J Funct Foods 2015,640:640–56. 200 
This review critically assessess the scientific evidence linking milk protein-derived peptides with 201 
health benefits in humans. 202 
*3. Patil P, Mandal S, Tomar SK, Anand S: Food protein-derived bioactive peptides in 203 
management of type 2 diabetes. Eur J Nutr 2015,54:863-80. 204 
This review contains up to date information on food protein-derived hydrolysates relevant to the 205 
management of type 2 diabetes. 206 
4. Méric E, Lemieux S, Turgeon SL, Bazinet L: Insulin and glucose responses after ingestion 207 
of different loads and forms of vegetable or animal proteins in protein enriched fruit 208 
beverages. J Funct Foods 2014,10:95-103. 209 
5. Manders RJ, Hansen D, Zorenc AH, Dendale P, Kloek J, Saris WH, van Loon LJ: Protein co-210 
ingestion strongly increases postprandial insulin secretion in type 2 diabetes patients. J Med 211 
Food 2014,17:758-63. 212 
6. Zhu C-F, Li G-Z, Peng H-B, Zhang F, Chen Y, Li Y: Treatment with marine collagen 213 
  13 
peptides modulates glucose and lipid metabolism in Chinese patients with type 2 diabetes 214 
mellitus. Appl Physiol Nutr Metab 2010,35:797-804. 215 
7. Juillerat-Jeanneret L: Dipeptidyl peptidase IV and its inhibitors: Therapeutics for type 2 216 
diabetes and what else? J Med Chem 2014,57:2197–212. 217 
8. Scheen AJ: A review of gliptins for 2014. Expert Opin Pharmacother 2015,16:43-62. 218 
9. Power O, Nongonierma AB, Jakeman P, FitzGerald RJ: Food protein hydrolysates as a 219 
source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 220 
diabetes. Proc Nutr Soc 2014,73:34-46. 221 
*10. Jao C-L, Hung C-C, Tung Y-S, Lin P-Y, Chen M-C, Hsu K-C: The development of 222 
bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the 223 
management of type 2 diabetes. BioMedicine 2015,5:9-15. 224 
This review contains current information relevant to food protein-derived hydrolysates with DPP-225 
IV inhibitory properties. 226 
11. Umezawa H, Aoyagi T, Ogawa K, Naganawa H, Hamada M, Takeuchi T: Diprotins A and 227 
B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot 1984,37:422-228 
5. 229 
**12. Nongonierma AB, FitzGerald RJ: An in silico model to predict the potential of dietary 230 
proteins as sources of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides. Food Chem 231 
2014,165:489–98. 232 
This study decribes the development of an in silico model to predict the potential of food proteins 233 
to act as a substrate for the geneartion of DPP-IV inhibitory peptides. The novelty of this in silico 234 
analysis relates to the fact that the model takes into account both the potency and occurrence of 235 
previously identified DPP-IV inhibitory peptides within the protein sequence. In addition, a 236 
peptide alignment strategy was reported to identifiy peptide features (i.e., Trp at the N terminus 237 
and/or Pro at position 2 of the peptide) of relatively potent DPP-IV inhibitors. 238 
  14 
13. Lacroix IME, Li-Chan ECY: Evaluation of the potential of dietary proteins as precursors 239 
of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. J Funct Foods 240 
2012,4:403-22. 241 
14. Nongonierma AB, FitzGerald RJ: Dipeptidyl peptidase IV inhibitory and antioxidative 242 
properties of milk-derived dipeptides and hydrolysates. Peptides 2013,39:157-63. 243 
15. Lacroix IME, Li-Chan ECY: Dipeptidyl peptidase-IV inhibitory activity of dairy protein 244 
hydrolysates. Int Dairy J 2012,25:97-102. 245 
16. Silveira ST, Martínez-Maqueda D, Recio I, Hernández-Ledesma B: Dipeptidyl peptidase-IV 246 
inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-247 
lactoglobulin. Food Chem 2013,141:1072–7. 248 
17. Hatanaka T, Inoue Y, Arima J, Kumagai Y, Usuki H, Kawakami K, Kimura M, Mukaihara T: 249 
Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food 250 
Chem 2012,134:797-802. 251 
18. Li-Chan ECY, Hunag S-L, Jao C-L, Ho K-P, Hsu K-C: Peptides derived from Atlantic 252 
salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. J Agric Food Chem 2012,60:973-8. 253 
19. Uenishi H, Kabuki T, Seto Y, Serizawa A, Nakajima H: Isolation and identification of 254 
casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-255 
type cheese and its effect on plasma glucose in rats. Int Dairy J 2012,22:24-30. 256 
20. Nongonierma AB, Le Maux S, Dubrulle C, Barre C, FitzGerald RJ: Quinoa (Chenopodium 257 
quinoa Willd.) protein hydrolysates with in vitro dipeptidyl peptidase IV (DPP-IV) 258 
inhibitory and antioxidant properties. J Cereal Sci 2015,65:112-8. 259 
21. Oseguera-Toledo ME, Gonzalez de Mejia E, Amaya-Llano SL: Hard-to-cook bean 260 
(Phaseolus vulgaris L.) proteins hydrolyzed by alcalase and bromelain produced bioactive 261 
peptide fractions that inhibit targets of type-2 diabetes and oxidative stress. Food Res Int 262 
2015,76:839–51. 263 
22. Nongonierma AB, FitzGerald RJ: Investigation of the potential of hemp, pea, rice and soy 264 
  15 
protein hydrolysates as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides. 265 
Food Dig 2015,6:19-29. 266 
23. Velarde-Salcedo AJ, Barrera-Pacheco A, Lara-González S, Montero-Morán GM, Díaz-Gois 267 
A, González de Mejia E, Barba de la Rosa AP: In vitro inhibition of dipeptidyl peptidase IV by 268 
peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) 269 
proteins. Food Chem 2013,136:758-64. 270 
24. Harnedy PA, FitzGerald RJ: In vitro assessment of the cardioprotective, anti-diabetic and 271 
antioxidant potential of Palmaria palmata protein hydrolysates. J Appl Phycol 2013,25:1793-272 
803. 273 
25. Harnedy PA, O’Keeffe MB, FitzGerald RJ: Purification and identification of dipeptidyl 274 
peptidase (DPP) IV inhibitory peptides from the macroalga Palmaria palmata. Food Chem 275 
2014,172:400-6. 276 
26. Nongonierma AB, FitzGerald RJ: Dipeptidyl peptidase IV inhibitory properties of a whey 277 
protein hydrolysate: Influence of fractionation, stability to simulated gastrointestinal 278 
digestion and food-drug interaction. Int Dairy J 2013,32:33–9. 279 
27. Lacroix IME, Li-Chan ECY: Isolation and characterization of peptides with dipeptidyl 280 
peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins. Peptides 281 
2014,54:39–48. 282 
28. Zhang Y, Chen R, Ma H, Chen S: Isolation and identification of dipeptidyl peptidase IV-283 
Inhibitory peptides from trypsin/chymotrypsin-treated goat milk casein hydrolysates by 284 
2D-TLC and LC–MS/MS. J Agric Food Chem 2015,63:8819-28. 285 
**29. Le Maux S, Nongonierma AB, Murray B, Kelly PM, FitzGerald RJ: Identification of 286 
short peptide sequences in the nanofiltration permeate of a bioactive whey protein 287 
hydrolysate. Food Res Int 2015,77:534-9. 288 
This study reports on the identification of short peptides within a membrane processed whey 289 
protein hydrolysate. Di- and tripeptides with DPP-IV inhibitory properties have, for the first time, 290 
  16 
been identified within a milk protein hydrolysate fraction using LC-MS/MS. 291 
30. Lacroix IM, Li-Chan EC: Comparison of the susceptibility of porcine and human 292 
dipeptidyl-peptidase IV to inhibition by protein-derived peptides. Peptides 2015,69:19-25. 293 
**31. Lacroix IM, Li-Chan ECY: Inhibition of dipeptidyl peptidase (DPP)-IV and α-294 
glucosidase activities by pepsin-treated whey proteins. J Agric Food Chem 2013,61:7500–6. 295 
This study describes the generation and characterisation of a peptic digest of α-lactalbumin with 296 
the most potent in vitro DPP-IV inhibitory activity reported to date in the litterature. 297 
32. Uchida M, Ohshiba Y, Mogami O: Novel dipeptidyl peptidase-4–inhibiting peptide 298 
derived from β-lactoglobulin. J Pharmacol Sci 2011,117:63-6. 299 
*33. Tulipano G, Faggi L, Nardone A, Cocchi D, Caroli AM: Characterisation of the potential 300 
of β-lactoglobulin and α-lactalbumin as sources of bioactive peptides affecting incretin 301 
function: In silico and in vitro comparative studies. Int Dairy J 2015,48:62-72. 302 
This study describes DPP-IV inhibitory peptide release from milk proteins using in silico 303 
digestion with gastrointestinal activities. Translation of the in silico outcomes to in vitro 304 
enzymatic digestion of individual milk proteins was then reported to validate the prediction. 305 
34. Tulipano G, Sibilia V, Caroli AM, Cocchi D: Whey proteins as source of dipeptidyl 306 
dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 2011,32:835-8. 307 
35. Hsu K-C, Tung Y-S, Huang S-L, Jao C-L. Dipeptidyl peptidase-IV inhibitory activity of 308 
peptides in porcine skin gelatin hydrolysates. In: Hernández-Ledesma B, editor. Bioactive 309 
Food Peptides in Health and Disease. http://www.intechopen.com/books/bioactive-food-peptides-310 
in-health-and-disease/dipeptidyl-peptidase-iv-inhibitory-activity-of-peptides-in-porcine-skin-311 
gelatin-hydrolysates. DOI: 10.5772/51264: In Tech; 2013. p. 205-18. 312 
36. Huang S-L, Hung C-C, Jao C-L, Tung Y-S, Hsu K-C: Porcine skin gelatin hydrolysate as a 313 
dipeptidyl peptidase IV inhibitor improves glycemic control in streptozotocin-induced 314 
diabetic rats. J Funct Foods 2014,11:235-42. 315 
  17 
37. Hatanaka T, Kawakami K, Uraji M: Inhibitory effect of collagen-derived tripeptides on 316 
dipeptidylpeptidase-IV activity. J Enzyme Inhib Med Chem 2014,29:823-8. 317 
38. Jin Y, Yan J, Yu Y, Qi Y: Screening and identification of DPP-IV inhibitory peptides 318 
from deer skin hydrolysates by an integrated approach of LC–MS/MS and in silico 319 
analysis. J Funct Foods 2015,18, Part A:344-57. 320 
39. Hsieh C, Wang T, Hung C, Chen M, Hsu K: Improvement of glycemic control in 321 
streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the 322 
dipeptidyl-peptidase IV inhibitor. Food Funct 2015,6:1887-92. 323 
40. Huang S-L, Jao C-L, Ho K-P, Hsu K-C: Dipeptidyl-peptidase IV inhibitory activity of 324 
peptides derived from tuna cooking juice hydrolysates. Peptides 2012,35:114-21. 325 
41. Cudennec B, Balti R, Ravallec R, Caron J, Bougatef A, Dhulster P, Nedjar N: In vitro 326 
evidence for gut hormone stimulation release and dipeptidyl-peptidase IV inhibitory 327 
activity of protein hydrolysate obtained from cuttlefish (Sepia officinalis) viscera. Food Res 328 
Int 2015,78:238-45. 329 
42. Connolly A, Piggott CO, FitzGerald RJ: In vitro α-glucosidase, angiotensin converting 330 
enzyme and dipeptidyl peptidase-IV inhibitory properties of brewers' spent grain protein 331 
hydrolysates. Food Res Int 2014,56:100-7. 332 
43. Mojica L, Chen K, de Mejía EG: Impact of commercial precooking of common bean 333 
(Phaseolus vulgaris) on the generation of peptides, after pepsin–pancreatin hydrolysis, 334 
capable to inhibit dipeptidyl peptidase-IV. J Food Sci 2015,80:H188-H98. 335 
44. Mochida T, Hira T, Hara H: The corn protein, zein hydrolysate, administered into the 336 
ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and 337 
dipeptidyl peptidase-IV activity in rats. Endocrinology 2010,151:3095-104. 338 
45. Wang F, Yu G, Zhang Y, Zhang B, Fan J: Dipeptidyl peptidase IV Inhibitory peptides 339 
derived from oat (Avena sativa L.), buckwheat (Fagopyrum esculentum), and highland 340 
barley (Hordeum vulgare trifurcatum (L.) Trofim) proteins. J Agric Food Chem 341 
  18 
2015,63:9543-9. 342 
46. Lacroix IME, Li-Chan ECY: Comparison of the susceptibility of porcine and human 343 
dipeptidyl-peptidase IV to inhibition by protein-derived peptides. Peptides 2015,69:19-25. 344 
47. Nongonierma AB, Mooney C, Shields DC, FitzGerald RJ: In silico approaches to predict 345 
the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) 346 
inhibitors. Peptides 2014,57:43-51. 347 
**48. Lacroix IM, Li-Chan EC: Peptide array on cellulose support - A screening tool to 348 
identify peptides with dipeptidyl-peptidase IV inhibitory activity within the sequence of α-349 
lactalbumin. Int J Mol Sci 2014,15:20846-58. 350 
Utilisation of a peptide array approach was described as a means to screen peptides originating 351 
from α-lactalbumin with DPP-IV inhibitory properties. 352 
49. Lafarga T, O’Connor P, Hayes M: Identification of novel dipeptidyl peptidase-IV and 353 
angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico 354 
analysis. Peptides 2014,59:53-62. 355 
50. Nongonierma AB, FitzGerald RJ: Inhibition of dipeptidyl peptidase IV (DPP-IV) by 356 
proline containing peptides. J Funct Foods 2013,5:1909–17. 357 
51. Lan VTT, Ito K, Ito S, Kawarasaki Y: Trp-Arg-Xaa tripeptides act as uncompetitive-type 358 
inhibitors of human dipeptidyl peptidase IV. Peptides 2014,54:166-70. 359 
52. Lan VTT, Ito K, Ohno M, Motoyama T, Ito S, Kawarasaki Y: Analyzing a dipeptide library 360 
to identify human dipeptidyl peptidase IV inhibitor. Food Chem 2015,175:66-73. 361 
**53. Hikida A, Ito K, Motoyama T, Kato R, Kawarasaki Y: Systematic analysis of a dipeptide 362 
library for inhibitor development using human dipeptidyl peptidase IV produced by a 363 
Saccharomyces cerevisiae expression system. Biochem Biophys Res Commun 2013,430:1217-364 
22. 365 
Peptide library approches have been described as a screening tool to identify DPP-IV inhibitory 366 
  19 
peptides. 367 
54. Rahfeld J, Schierborn M, Hartrodt B, Neubert K, Heins J: Are diprotin A (Ile-Pro-Ile) and 368 
diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim 369 
Biophys Acta, Prot Struct Mol Enzymol 1991,1076:314-6. 370 
*55. Nongonierma AB, FitzGerald RJ: Susceptibility of milk protein-derived peptides to 371 
dipeptidyl peptidase IV (DPP-IV) hydrolysis. Food Chem 2014,145:845–52. 372 
Milk protein-derived peptides which were predicted to be released from milk proteins using 373 
gastrointestinal activities were shown to act as DPP-IV substrates. A milk protein-derived peptide 374 
Leu-Pro-Leu-Pro-Leu was, for the first time, shown to act as pro-drug inhibitor of DPP-IV. 375 
56. Nongonierma AB, FitzGerald RJ: Utilisation of the isobole methodology to study dietary 376 
peptide–drug and peptide–peptide interactive effects on dipeptidyl peptidase IV (DPP-IV) 377 
inhibition. Food Funct 2015,6:312-9. 378 
57. Wang T-Y, Hsieh C-H, Hung C-C, Jao C-L, Chen M-C, Hsu K-C: Fish skin gelatin 379 
hydrolysates as dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 stimulators 380 
improve glycaemic control in diabetic rats: A comparison between warm- and cold-water 381 
fish. J Funct Foods 2015,19, Part A:330-40. 382 
58. Jakubowicz D, Froy O, Ahrén B, Boaz M, Landau Z, Bar-Dayan Y, Ganz T, Barnea M, 383 
Wainstein J: Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in 384 
type 2 diabetes: A randomised clinical trial. Diabetologia 2014,57:1807-11. 385 
**59. Boutrou R, Gaudichon C, Dupont D, Jardin J, Airinei G, Marsset-Baglieri A, Benamouzig 386 
R, Tomé D, Leonil J: Sequential release of milk protein–derived bioactive peptides in the 387 
jejunum in healthy humans. Am J Clin Nutr 2013,97:1314-23. 388 
This study has demonstrated the presence of milk protein-derived peptides in the jejunum fluid of 389 
humans which was collected using nasogastric tubes. 390 
  20 
*60. Nongonierma AB, FitzGerald RJ: Bioactive properties of milk proteins in humans: A 391 
review. Peptides 2015,73:20-34. 392 
This review presents the scientific information linking the ingestion of intact milk proteins to a 393 
range of bioactive properties in humans. 394 
 395 
 396 
  21 
Table captions 
Table 1. Summary of the outcomes of animal studies conducted with food protein-derived 
hydrolysates displaying dipeptidyl peptidase IV (DPP-IV) inhibitory properties. 
 
Table 2. Peptides originating from bovine -casein identified in the jejunum of human 
subjects which display in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Adapted 
from Boutrou et al. [59]. 
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Table 1 
Compound Study design Biological outcomes Reference 
Zein (ZH) and meat 
protein hydrolysates 
(MPH) 
Animals: 7 week old ♂ Sprague-Dawley rats 
(n=6/group) 
Dose: 2 g kg
-1 
direct ileal
 
administration 
Duration: acute 
 
Antidiabetic effects observed with ZH only but 
not MPH. 
- Increased total & active GLP-1 secretion from 
L cells 
- Reduced plasma DPP-IV activity 
- Increased insulin secretion 
- Reduced glycaemia 
[44] 
-Lactoglobulin 
hydrolysed with trypsin 
Animals: C57BL/6 mice (n=10/group) 
Dose: 300 mg kg
-1
 oral gavage 
Duration: acute 
- Reduced glycaemia following an OGTT [32] 
LPQNIPPL
a
 (-casein (f 
70-77)) 
Animals: 8 week old ♀ Sprague-Dawley 
(n=12/group) 
Dose: 300 mg kg
-1
 oral gavage 
Duration: acute 
- Reduced glycaemia following an OGTT 
- No effect on plasma insulin levels 
 
[19] 
Porcine skin gelatin 
hydrolysed with 
Flavourzyme
TM
 
Animals:8 weeks ♂ Sprague-Dawley 
streptozotocin (STZ)-induced diabetic rats 
(n=12/group) 
Dose: 300 mg day
-1
 oral gavage 
Duration: 42 days 
- Increased active plasma GLP-1 secretion 
- Reduced plasma DPP-IV activity 
- Increased plasma insulin levels 
- Increased plasma glucagon levels 
- Reduced glycaemia following an OGTT 
[36] 
Atlantic salmon skin 
gelatin hydrolysed with 
Flavourzyme
TM
 
Animals: ♂ Sprague-Dawley STZ-induced diabetic 
rats (n=12/group) 
Dose: 300 mg day
-1
 oral gavage 
Duration: 5 weeks 
- Increased total & active plasma GLP-1 
secretion 
- Reduced plasma DPP-IV activity 
- Increased plasma insulin levels 
- Increased insulin:glucagon ratio 
- Reduced glycaemia following an OGTT 
[39] 
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Tilapia (TSGH) and 
halibut (HSGH) skin 
gelatin hydrolysed with 
Flavourzyme
TM
 
Animals: ♂ Sprague-Dawley STZ-induced diabetic 
rats (n=11/group) 
Dose: 750 mg kg
-1
 day
-1
 oral gavage 
Duration: 30 days 
- Increased total plasma GLP-1 secretion with 
TSGH and HSGH 
- Reduced plasma DPP-IV activity with TSGH 
and not HSGH 
- Increased plasma insulin levels, being more 
marked with TSGH than with HSGH 
- Reduced glycaemia following an OGTT, being 
more marked with TSGH than with HSGH 
[57] 
a
peptide sequence with the one letter amino acid code. 
DPP-IV: dipeptidyl peptidase IV; GLP-1: glucagon like peptide 1; HSGH: halibut skin gelatin hydrolysate; MPH: meat protein hydrolysate; OGTT: oral 
glucose tolerance test; STZ: streptozotocin; TSGH: tilapia skin gelatin hydrolysate; ZH: zein hydrolysate; ♀: female; ♂: male. 
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Table 2 
 
Peptide fragment Compound
a
 DPP-IV IC50 value (µM)
b
 Reference
c
 
60-68 YPFPGPIPN 670 [19] 
62-68 FPGPIPN 260 [19] 
70-77 LPQNIPPL 46 [19] 
71-77 PQNIPPL 1500 [19] 
74-82 IPPLTQTPV 1300 [19] 
135-139 LPLPL 325 [50] 
- Sitagliptin 3910-3 [56] 
a
The peptide sequences are abbreviated with the one letter amino acid code 
b
IC50: half maximal inhibitory concentration 
c
Bibliographic reference reporting the in vitro IC50 value 
 
